At Elanco, we provide those who raise and care for animals with solutions that empower them to advance a vision of food and companionship enriching life.
We understand the powerful role healthy animals play in making lives better. As pets increasingly become important parts of our families, so too does the need to help them live longer, healthier, higher-quality lives. As the global population grows, so too will the need to meet the demand for safe, affordable food for all.
Since our start at Eli Lilly and Company in 1954, Elanco has been working to empower our customers—from veterinarians to food producers to all those concerned with animal health—to address these global challenges, and advance a vision of food and companionship enriching life. We strive to develop and deliver products safe for consumers, animals and the environment through innovation and a shared vision to enrich the life of people worldwide.
Our Mission: We provide those who raise and care for animals with a comprehensive set of animal health products and knowledge services that empower them to address the global challenges of a diverse and changing world.
Our Vision: Food and Companionship Enriching Life
We are proud of our heritage of close customer relationships, scientific rigor and quality products, from the development of the first antibiotic for veterinary use in 1953 to today’s treatments that address the health needs of our pets. At the same time, we are humbled by the global challenges ahead and we will remain true to our heritage and our values to provide needed solutions in the field of animal health.
Elanco has helped shape the lives of animals and their human companions for more than half a century. Explore the timeline below to learn more.
Since 2008, Jeff Simmons has served as President of Elanco, the animal health division of Eli Lilly and Company, (NYSE: LLY). As part of this role, he is also a Senior Vice President and Executive Officer of Lilly. Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. As a leading global animal health company, Elanco values innovation, both in scientific research and daily operations, and strives to cultivate a collaborative work environment for more than 6,500 employees worldwide through its vision of Food and Companionship Enriching Life.
In more than two decades with the company, Simmons has held a number of sales, marketing and management positions, in the United States and abroad, including serving as country director in Brazil and area director for West Europe based in the U.K.
These international experiences offered Simmons a new perspective on food and agriculture and created a deep conviction about the need for solutions to global food security. Elanco is bringing this vision to life via a commitment to end hunger for 100,000 families globally through a partnership with Heifer International, and begin breaking the cycle of hunger in 100 communities around the globe. Simmons has become an active advocate for the role technology plays in sustainable, efficient production of safe and affordable protein. He has published white papers on this topic, most recently, the ENOUGH report at www.ENOUGHmovement.com, and actively engages in food security discussions in social media on Twitter @JeffSimmons2050.
Simmons has held numerous leadership positions, including past board member of Chiquita Brands and former President of the International Federation of Animal Health (IFAH).
Ramiro Cabral currently serves as Vice President of Elanco Operations for Europe, Middle East and Africa. Since July of 2015, he has been responsible for Elanco business in Europe, Middle East and Africa. Prior to this, he held the position of Area Director for Western Europe.
Since joining Elanco in 1998, Dr. Cabral has held a number of management positions within the company, including Technical Sales at Elanco Argentina, Global Marketing Manager, Beef Business Unit Director in the U.S. Affiliate, and Affiliate Director at Elanco Canada.
Dr. Cabral earned a DVM degree at UNICEN, Argentina in 1995 and an MBA from Purdue University in 2005. He joined Elanco after working some years in his family’s farm and working as a consultant in the Veterinary and Agribusiness industry.
In June of 2014, Tony Ezell was appointed Chief Marketing Officer of Elanco. Ezell joined Lilly in 1992, and over his 22 years has held many roles in sales, marketing and general management. From 1999 to 2007, Ezell held various leadership positions including executive director of marketing for the endocrine business unit, as well as business unit leader of the US acute care business.
In more recent years Ezell has been a leader in Lilly’s market research organization where he first served as executive director of market research for Lilly USA. In 2009, Ezell was promoted to vice president, global market research, and in November 2012 he was promoted to chief customer officer Eli Lilly and Company. As chief customer officer, he was responsible for leading Lilly’s enterprise level customer experience strategy as well as delivering on Lilly’s marketing and market research capability strategy. His focus was on ensuring the company consistently connects innovative science with relevant customer experiences necessary to deliver on both our product and corporate brand promises.
Ezell has global experience in developing deep customer understanding and translating that understanding into meaningful brand campaigns. He is experienced in leading major transformation that spans business units, functions and geographies.
Born in Mobile, Alabama, Ezell has a degree in Business Administration from the School of Business and Industry (SBI) at Florida A & M University, an Executive Education Certificate from Wharton and a Masters in Business from the Kellogg School of Management at Northwestern University.
Ezell serves on the Leadership Advisory Council for Providence Cristo Rey High School and is the Chairman of the UNCF Indiana Leadership Council. He is on the Board of Trustees for the Marketing Science Institute, KPMG Healthcare Advisory Board and served on the Board of Directors for the Health Forum, LLC from 2006-2012.
Eric Graves is the President of North American Commercial Operations and is responsible for the company's U.S. and Canadian commercial business operations. Graves joined Elanco, the animal health division of Eli Lilly and Company in 2003 and has held a range of management roles and responsibilities.
Prior to his current role, he was Vice President of Integration Planning for the Novartis Acquisition and led a complex, but successful integration over the last year. Previously, Graves was Elanco’s Chief Marketing Officer and responsible for all aspects of marketing for existing and new products and brands. He led Elanco’s launch into the companion animal market, where he enjoyed being part of building a team and business that created growth and value for customers. Part of this time he was based in Europe, working on the global companion animal health business with additional emphasis on integrating a previous acquisition.
Prior to joining Elanco, Graves served as a director of veterinary marketing at Hill’s Pet Nutrition, Inc., a division of Colgate-Palmolive. He has also held a variety of positions in companion animal marketing, sales and operations at both Merial and Merck Agvet.
Ralph Heuser came onboard as the Vice President for Elanco Asia Pacific effective January 1st, 2015 bringing with him vast and valuable experience in the animal health business.
Prior to Elanco, Heuser had previously served as the Region Head Europe for Novartis Animal Health. He first worked for Pfizer, starting in 1994, as regional Key Account Manager, where he spent much time on the road and with customers. He says his company car became his office and the intense customer interaction greatly benefited him in later positions in sales, marketing and management.
Heuser then moved to become a Farm Animal Business Product Manager for Boehringer in 1996 and later joined Novartis as Head Marketing and Sales for the Human Medical Nutrition business (now part of Nestlé). During more than 18 years with Novartis and Novartis Animal Health he served in management positions for various countries in Central Europe as well as in Germany and Australia & New Zealand. Most recently, he held the role as Head of Global Sales Excellence and was appointed Head of Region Europe in 2013.
Heuser studied agricultural economics at the University in Bonn, Germany and received a doctorate in macroeconomics from the same university.
Stephen H. Jenison is the Senior Vice President of Elanco Manufacturing. He oversees internal manufacturing operations at facilities in the United States and multiple other countries. In addition, he oversees Elanco’s global external manufacturing operations and supply chain organizations.
Born in Paris, Illinois, Jenison was awarded a Bachelor of Science degree in chemical engineering from Rose-Hulman Institute of Technology in 1981, and a master in business administration from the University of Kansas in 1985.
Jade Kas currently leads HR at Elanco. He joined Eli Lilly and Company in 1999 and spent his first four years in both sales and sales operations roles.
During the past 12 years, he has held a variety of roles in Human Resources supporting sales and marketing, global compensation, mergers and acquisitions, employee relations, and manufacturing.
In his spare time, Kas enjoys spending time with his family, volunteering to coach his kids sporting activities, strength training, and traveling with his family. Kas holds a bachelor's degree in Business Management & HR Management from IUPUI.
Brian Kopp has been with Eli Lilly and Company for 19 years, holding a variety of positions including Director and Sr. Director, Finance, Lilly USA Pharmaceutical Operations; Manager, Corporate Strategy and Planning; and Sr. Analyst, Corporate Finance and Investment Banking.
Prior to joining Eli Lilly and Company, Kopp worked in various financial and business development roles at General Motors Corporation, including capital planning, business unit finance, manufacturing, as well as international treasury and business development support, primarily focused on Latin America.
Kopp sits on the Investment Committee of Lynx Capital Corporation, a fund dedicated to providing growth capital to minority owned businesses in Indiana.
He grew up in Northern Kentucky and Southern Indiana and holds a bachelor’s degree in finance from Indiana University, and a Master’s in Business Administration from Butler University.
John F. Kuckelman has served as General Counsel since August 2014. Kuckelman leads a global team of legal professionals, with responsibilities for the legal affairs of Elanco around the world.
Before assuming his current role, Kuckelman was Eli Lilly and Company’s General Counsel for Asia Operations, and was based in Hong Kong, China. Kuckelman also previously served as Lilly’s Global Anti-Corruption Counsel for four years. Before joining Lilly in August 2007, Kuckelman was a partner at Shook, Hardy & Bacon, where he defended pharmaceutical companies in litigation throughout the United States.
Kuckelman earned his Juris Doctor from the Notre Dame Law School, magna cum laude, in 1999, where he studied international law at Notre Dame’s London Law Centre. From 1995-96, Kuckelman studied as an Ambassadorial Fellow through Rotary International at Eberhard-Karls Universitaet Tuebingen, in Tuebingen, Germany, where he pursued graduate studies in Government and History. Kuckelman earned his B.A. in history and political science from Washburn University in 1994.
Julie Lawless is Sr. Director of Corporate Affairs at Elanco, the animal health division of Eli Lilly and Company, (NYSE: LLY). In this role, she oversees global and regional communications, government affairs, corporate branding, cause & shared value and the Elanco Pulse Institute social listening center.
Lawless joined Elanco at the Greenfield, Indiana headquarters in 2014 as Director of Corporate Communications. Under her leadership, the function has developed into a global capability with industry-leading corporate reputation initiatives.
She has a broad range of experiences in corporate affairs from several industries, including technology, automotive and food manufacturing. Most recently, Lawless worked in corporate communications, issues management and consumer relations at Mars, Incorporated, within the petcare segment. Before Mars, she spent several years at Nissan North America’s manufacturing plant and headquarters campus in Nashville, Tennessee in internal, regional, and product communications. She started her career as a field producer and reporter at KPLR-TV in St. Louis before moving to corporate public relations.
With a passion for pets, Lawless currently serves on the board for Elanco’s Companionship Cause, which focuses on service and therapy animals, as well as bringing the health benefits of pets to life.
Lawless currently serves as the communications chairperson for the Health for Animals organization representing the animal health sector.
Patrick Lenihan was appointed Elanco’s Chief Operating Officer in March of 2017. Since joining Eli Lilly and Company (NYSE: LLY) in 2004, Lenihan has held various leadership roles in Six-Sigma, Human Resources, and Finance.
Lenihan has a track record of leading large, complex organizations and functions through change. Most recently, Lenihan had oversight of the financial and strategic operations for Lilly's Emerging Markets division, including responsibility for the division’s annual and strategic planning exercises. Prior to that he held leadership roles as the Finance Director of Lilly’s Insulin API manufacturing plants in Indianapolis and the Director of Global Travel & Meetings for the company.
Lenihan earned his undergraduate degree in Management from the Krannert School of Management at Purdue University, magna cum laude, in 2000. He earned his M.B.A. in Finance, Marketing, and Biotechnology from the Kellogg School of Management at Northwestern University in 2008.
Patrick currently serves on the board of the Starfish Initiative and was formerly the Chairman of the Board at Outreach Inc.
Michael Morgan, Senior Director of Ethics and Compliance is currently based at the Greenfield, Indiana headquarters.
Morgan has worked for Eli Lilly in the pharmaceutical industry for 30 years, including his current role in Elanco since September 2013. Prior to his current role, Morgan was the Senior Director of Ethics and Compliance for Europe, Canada and Australia from 2009-2013 and was Director of Ethics and Compliance at the Lilly Corporate Headquarters and in the US affiliate in Indianapolis, from 2005 to 2009. Morgan has worked in a variety of other functions within Lilly including Sales/Sales Management, Marketing/Pricing, Health Economics/Health Outcomes and worked at PCS Health Systems in Disease Management.
He received his Bachelor of Science degree in Molecular and Cell Biology from Pennsylvania State University and his Master of Science in Business Management, Purdue University.
He holds certifications in Health Care Compliance Certification Seton Hall University Law School and Certified Compliance and Ethics Professional since 2009 from the Society of Corporate Compliance and Ethics.
Aaron Schacht is currently the Vice President for Global Research and Development.
Prior to this, Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit.
Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up.
Previously, Schacht held roles as Managing Director of Lilly University, Director of Knowledge Management, and Manager of Strategy and Productivity for Discovery Research.
Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Dr. José Manuel Correia de Simas is currently responsible for Latin America Business. Simas joined Elanco in 2000 in Brazil where he held a technical role for cattle products. He moved to global marketing in a technical support role in 2002 and moved to the United States. In 2004, Simas took on the responsibility for the Argentina and Chile operations. In late 2005, he moved to Vienna, Austria to serve as area director for Elanco’s operations in Central-Eastern Europe/North Africa/Middle Eastern markets. Simas also led the U.S. beef business from 2008 to 2011. He has also lead B2B and Global Accounts and, prior to his actual position, has held Product Development, Regulatory and R&D operations.
Simas received a bachelor’s from the Federal University of Lavras in Brazil. He also holds a master’s and a doctorate in Animal Nutrition and Physiology from the University of Arizona, USA, as well as a post doctorate from the University of Sao Paulo, Brazil.
Jacques Zimmowitch is Vice President of Global Quality.
Prior to this, Zimmowitch was Vice President of Global Quality for Drug Product Operations for Americas and Asia and Global Computer System Operations for Eli Lilly and Company. In this capacity, he provided strategic direction and was responsible for Good Manufacturing Practices (GMP) compliance at the company’s Drug Product, Device and Distribution Operations in the Americas and Asia and for overall quality of the Lilly US Sales and Marketing affiliates. He also provided ultimate quality oversight for Consumer Product Quality Assurance (Complaints) programs globally and led the Parenteral Network Quality Steering Team, setting technical direction for quality and sterility assurance activities at these manufacturing sites. Zimmowitch was a member of Eli Lilly’s Manufacturing Policy Committee which is the governing body for Manufacturing and Supply Chain for Eli Lilly’s global manufacturing operations.
Zimmowitch joined Lilly initially in 1991and held multiple assignments in France and in the US through 2007 covering: Technical Services/Manufacturing Science, Quality Control Laboratory, Global Supply Chain, Operational Manufacturing and both Manufacturing Sites Quality Assurance and Global Quality Assurance. For two years, he led the Quality and Regulatory organization of Becton Dickinson, Pharmaceutical Systems business unit, before he rejoined Lilly in October 2009.
Zimmowitch was born and raised in France and holds a Master of Science (DEA Biology/Physiology) from France University of Paris and a Master of Business (Essec – France).
Jacques represented Eli Lilly and Company and the Pharmaceutical Industry as a member of the PhRMA GQMC (Global Quality and Manufacturing Committee).